RecruitingNCT05905705

Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy

Sponsor

Washington University School of Medicine

Enrollment

50 participants

Start Date

Mar 7, 2023

Study Type

OBSERVATIONAL

Conditions

Treatment Resistant Depression

Summary

Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.

Eligibility

Min Age: 21 YearsMax Age: 65 Years

Inclusion Criteria1

Referral for initial ECT index course for Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression. Historic failure of response or remission to at least two antidepressant medications of sufficient dose and duration will be used for TRD diagnostic.

Exclusion Criteria2

Diagnoses of schizophrenia or schizoaffective disorders.
Subjects who are unable to tolerate the Dreem device for sleep recordings will be excluded from the study.

Interventions

DIAGNOSTIC_TESTElectroencephalography (EEG)

High-density EEG will be acquired during resting wakefulness before each ECT session.

DIAGNOSTIC_TESTQuantitative Measurements of Sleep Microstructure

Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.

Locations(1)

Washington University School of Medicine/Barnes-Jewish Hospital

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05905705

Related Trials

Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression

NCT071662891 location